Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA 99210, USA.
Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Cancer Cell. 2017 Mar 13;31(3):368-382. doi: 10.1016/j.ccell.2017.02.003.
Metastasis is a predominant cause of death for prostate cancer (PCa) patients; however, the underlying mechanisms are poorly understood. We report that monoamine oxidase A (MAOA) is a clinically and functionally important mediator of PCa bone and visceral metastases, activating paracrine Shh signaling in tumor-stromal interactions. MAOA provides tumor cell growth advantages in the bone microenvironment by stimulating interleukin-6 (IL6) release from osteoblasts, and triggers skeletal colonization by activating osteoclastogenesis through osteoblast production of RANKL and IL6. MAOA inhibitor treatment effectively reduces metastasis and prolongs mouse survival by disengaging the Shh-IL6-RANKL signaling network in stromal cells in the tumor microenvironment. These findings provide a rationale for targeting MAOA and its associated molecules to treat PCa metastasis.
转移是导致前列腺癌 (PCa) 患者死亡的主要原因;然而,其潜在机制尚不清楚。我们报告单胺氧化酶 A (MAOA) 是 PCa 骨和内脏转移的临床和功能上重要的介质,通过在肿瘤-基质相互作用中激活旁分泌 Shh 信号来发挥作用。MAOA 通过刺激成骨细胞释放白细胞介素-6 (IL6),为肿瘤细胞在骨微环境中提供生长优势,并通过成骨细胞产生 RANKL 和 IL6 激活破骨细胞生成,从而引发骨骼定植。MAOA 抑制剂通过在肿瘤微环境中的基质细胞中解除 Shh-IL6-RANKL 信号网络,有效地减少转移并延长小鼠的存活时间。这些发现为靶向 MAOA 及其相关分子治疗 PCa 转移提供了依据。